National Institute on Drug Abuse; Notice of Closed Meeting, 36429-36430 [2010-15490]

Download as PDF Federal Register / Vol. 75, No. 122 / Friday, June 25, 2010 / Notices Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before July 28, 2010. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before July 20, 2010. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by July 21, 2010. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Diem-Kieu Ngo at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at https://www.fda.gov/ AdvisoryCommittees/AboutAdvisory Committees/ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). mstockstill on DSKH9S0YB1PROD with NOTICES Dated: June 18, 2010. Thinh Nguyen, Acting Associate Commissioner for Special Medical Programs. [FR Doc. 2010–15504 Filed 6–24–10; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Closed Meeting National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Initial Review Group Obstetrics and Maternal-Fetal Biology Subcommittee. Date: July 12, 2010. Time: 8:30 a.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: Legacy Hotel and Meeting Center, 1775 Rockville Pike, Rockville, MD 20852. Contact Person: Peter Zelazowski, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child, Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–435–6902, PETER.ZELAZOWSKI@NIH.GOV. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: June 21, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–15491 Filed 6–24–10; 8:45 am] BILLING CODE P VerDate Mar<15>2010 18:36 Jun 24, 2010 Jkt 220001 36429 PO 00000 Frm 00084 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Medications Development for Substance Related Disorders (R01). Date: July 7–8, 2010. Time: 9 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 20037. Contact Person: Jose F. Ruiz, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892. 301–451–3086. ruizjf@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Medications Development for CannabisRelated Disorders (R01). Date: July 8, 2010. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 20037. Contact Person: Jose F. Ruiz, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892. 301–451–3086. ruizjf@nida.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA– K Conflicts SEP. Date: July 13, 2010. Time: 5:30 p.m. to 7:30 p.m. Agenda: To review and evaluate grant applications. Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202. Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401. 301–451–4530. elazarwe@nida.nih.gov. E:\FR\FM\25JNN1.SGM 25JNN1 36430 Federal Register / Vol. 75, No. 122 / Friday, June 25, 2010 / Notices Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Deep Sequencing and Analysis of Pharmacogenomic Regions. Date: July 14, 2010. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Minna Liang, PhD, Scientific Review Administrator, Training and Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892. 301–435–1432. liangm@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: June 18, 2010. Anna P. Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–15490 Filed 6–24–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings mstockstill on DSKH9S0YB1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Clinical Neuroimmunology and Brain Tumors. Date: July 7, 2010. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call.) Contact Person: Samuel C. Edwards, PhD, Chief, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5210, MSC 7846, Bethesda, MD 20892. (301) 435–1246. edwardss@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing VerDate Mar<15>2010 16:23 Jun 24, 2010 Jkt 220001 limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, Fellowships: Risk Prevention and Health Behavior. Date: July 9, 2010. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036. Contact Person: Michael Micklin, PhD, Chief, RPHB IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3136, MSC 7759, Bethesda, MD 20892. (301) 435–1258. micklinm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Quick Trials on Imaging and Image-guided Intervention. Date: July 12, 2010. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting.) Contact Person: John Firrell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, MSC 7854, Bethesda, MD 20892. 301–435– 2598. firrellj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Neurotechnology Overflow. Date: July 14, 2010. Time: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call.) Contact Person: Robert C. Elliott, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5190, MSC 7846, Bethesda, MD 20892. 301–435– 3009. elliotro@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, NIH Director’s ARRA Funded Pathfinder Award to Promote Diversity in the Scientific Workforce (RFA OD–10–013). Date: July 15–16, 2010. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: John Firrell, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, MSC 7854, Bethesda, MD 20892. 301–435– 2598. firrellj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, RFA Panel: CounterAct—Countermeasures Against Chemical Threats. Date: July 15, 2010. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00085 Fmt 4703 Sfmt 9990 Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314. Contact Person: Jonathan K. Ivins, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040A, MSC 7806, Bethesda, MD 20892. (301) 594– 1245. ivinsj@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business: Arthritis, Connective Tissue, and Skin (ACTS). Date: July 15, 2010. Time: 8:30 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Aftab A. Ansari, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892. 301–594– 6376. ansaria@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Molecular and Cellular Neuroscience. Date: July 15, 2010. Time: 11 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call.) Contact Person: Carole L. Jelsema, PhD, Chief and Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4176, MSC 7850, Bethesda, MD 20892. (301) 435– 1248. jelsemac@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Member Conflict: Musculoskeletal Rehabilitation Applications. Date: July 22, 2010. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call.) Contact Person: Aftab A. Ansari, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD 20892. 301–594– 6376. ansaria@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: June 21, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2010–15486 Filed 6–24–10; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\25JNN1.SGM 25JNN1

Agencies

[Federal Register Volume 75, Number 122 (Friday, June 25, 2010)]
[Notices]
[Pages 36429-36430]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-15490]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
USC, as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Medications Development for Substance Related 
Disorders (R01).
    Date: July 7-8, 2010.
    Time: 9 a.m. to 1 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 
20037.
    Contact Person: Jose F. Ruiz, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892. 301-451-3086. ruizjf@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Medications Development for Cannabis-Related 
Disorders (R01).
    Date: July 8, 2010.
    Time: 1 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC 
20037.
    Contact Person: Jose F. Ruiz, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892. 301-451-3086. ruizjf@nida.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, NIDA-K Conflicts SEP.
    Date: July 13, 2010.
    Time: 5:30 p.m. to 7:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes 
Street, Arlington, VA 22202.
    Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401. 301-451-4530. elazarwe@nida.nih.gov.

[[Page 36430]]

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, Deep Sequencing and Analysis of Pharmacogenomic 
Regions.
    Date: July 14, 2010.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Minna Liang, PhD, Scientific Review 
Administrator, Training and Special Projects Review Branch, Office 
of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 
220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892. 301-435-
1432. liangm@nida.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: June 18, 2010.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-15490 Filed 6-24-10; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.